Instillation Therapy in Superficial Urinary Bladder Cancer
Authors:
- Finnbladder GroupFGFinnbladder Group
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 25 (sup138) , 179-185
Abstract
Carcinoma in situ (TIS) is a special dilemma. Controversial diagnostic and therapeutic attitudes prevail in the literature. Mild dysplasia grad 1 seems to be a condition where ‘wait-and-see policy’ might be justified according to our series of 60 patients with a TIS whereas, both the TISG2 and TISG3 are real malignancies which need a more aggressive treatment than a transurethral resection (TUR) alone. Under a close control, intravesical chemo-and immunotherapy offer an alternative to cystectomy. On the other hand, for a visible superficial (Ta-Tl) cancer TUR is the principal treatment, which can easily be repeated. Anyhow, the high frequency of recurring tumours and the tendency to simultaneous progression in a specific category of patients have led to adjuvant prophylactic treatments. Currently, both intravesical cytostatics and intravesical bacillus Calmette-Guérin have been proven safe with much the same effect. Adjuvant prophylaxis of a primary, single superficial tumour is not indicated, even though the treatment of TIG3 cancer is under discussion.Keywords
This publication has 10 references indexed in Scilit:
- Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder CancerEuropean Urology, 1991
- Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder CancerJournal of Urology, 1988
- Statistical and epidemiologic data on urologic cancerCancer, 1987
- Effect of Mitomycin C and Doxorubicin Instillation on Carcinoma in situ of the Urinary BladderEuropean Urology, 1986
- Methodologies for quantifying the results of intravesical chemotherapy of superficial tumors of the bladderMedical Oncology and Tumor Pharmacotherapy, 1985
- Detecting mitomycin C in human plasma during intravesical therapyInternational Urology and Nephrology, 1985
- The Management of Superficial Bladder Tumors and Carcinoma in situ with Intravesical Bacillus Calmette-GuerinJournal of Urology, 1985
- Welche oberflächlichen Übergangszellkarzinome der Harnblase sollten adjuvant chemotherapeutisch behandelt werden?Aktuelle Urologie, 1985
- Tigason® (Etretinate) in Prevention of Recurrence of Superficial Bladder TumorsEuropean Urology, 1983
- Intravesical Instillation of Adriamycin®European Urology, 1980